Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trialRavi A. Madan, James L. Gulley, Myrna Rauckhorst et al.|The Lancet Oncology|2012Cited by 327
Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancerJames L. Gulley, Jeffrey Schlom, Philip M. Arlen et al.|Cancer Immunology Immunotherapy|2009Cited by 298